Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 500

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study

Open access
van der Valk, Mirthe Emilie, Mangen, Marie-Josée J, Leenders, Max, Dijkstra, Gerard, van Bodegraven, Ad A, Fidder, Herma H, de Jong, Dirk J, Pierik, Marieke, van der Woude, C Janneke, Romberg-Camps, Mariëlle J L, Clemens, Cees HM, Jansen, Jeroen M, Mahmmod, Nofel, van de Meeberg, Paul C, van der Meulen-de Jong, Andrea E, Ponsioen, Cyriel Y, Bolwerk, Clemens JM, Vermeijden, J Reinoud, Siersema, Peter D, van Oijen, Martijn GH, Oldenburg, Bas, on behalf of the COIN study group and the Dutch Initiative on Crohn and Colitis · 2014 · Gut

Abstract

Objective: The introduction of anti tumour necrosis factor-α (anti-TNFα) therapy might impact healthcare expenditures, but there are limited data regarding the costs of inflammatory bowel diseases (IBD) following the introduction of these drugs. We aimed to assess the healthcare costs and productivity losses in a large cohort of IBD patients. Design: Crohn's disease (CD) and ulcerative colitis (UC) patients from seven university hospitals and seven general hospitals were invited to fill-out a web-based questionnaire. Cost items were derived from a 3 month follow-up questionnaire and categorised in outpatient clinic, diagnostics, medication, surgery and hospitalisation. Productivity losses included sick leave of paid and unpaid work. Costs were expressed as mean 3-month costs per patients with a 95% CI obtained using non-parametric bootstrapping. Results: A total of 1315 CD patients and 937 UC patients were included. Healthcare costs were almost three times higher in CD as compared with UC, €1625 (95% CI €1476 to €1775) versus €595 (95% CI €505 to €685), respectively (p<0.01). Anti-TNFα use was the main costs driver, accounting for 64% and 31% of the total cost in CD and UC. Hospitalisation and surgery together accounted for 19% and <1% of the healthcare costs in CD and 23% and 1% in UC, respectively. Productivity losses accounted for 16% and 39% of the total costs in CD and UC. Conclusions: We showed that healthcare costs are mainly driven by medication costs, most importantly by anti-TNFα therapy. Hospitalisation and surgery accounted only for a minor part of the healthcare costs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/gutjnl-2012-303376

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 26 references

Research works printed but not linked: 4

  1. 10.1136/ard.2005.039420 · doi:10.1136/ard.2005.039420
  2. 10.1002/art.10998 · doi:10.1002/art.10998
  3. 10.1136/ard.2005.047175 · doi:10.1136/ard.2005.047175
  4. Cosnes, 2008, Crohn's disease phenotype, prognosis, and long-term complications: what to expect, Acta Gastroenterol Belg, 71, 303

Cited by

See all 500

Metadata

Authors
van der Valk, M. E., Mangen, M.-J. J., Leenders, M., Dijkstra, G., van Bodegraven, A. A., Fidder, H. H., de Jong, D. J., Pierik, M., van der Woude, C. J., Romberg-Camps, M. J. L., Clemens, C. H., Jansen, J. M., Mahmmod, N., van de Meeberg, P. C., van der Meulen-de Jong, A. E., Ponsioen, C. Y., Bolwerk, C. J., Vermeijden, J. R., Siersema, P. D., van Oijen, M. G., Oldenburg, B., & on behalf of the COIN study group and the Dutch Initiative on Crohn and Colitis
Venue
Gut
Publisher
BMJ
Published
2012-11-07
Volume
63
Issue
1
Pages
72-79
ISSN
  • 0017-5749 (ISSN-L)
  • 1468-3288
OpenAlex
W2169467558
Cited by
500
References
26
FWCI
13.82
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study. https://app.cochat.ai/papers/10.1136/gutjnl-2012-303376
The paper
van der Valk, M. E., Mangen, M.-J. J., Leenders, M., Dijkstra, G., van Bodegraven, A. A., Fidder, H. H., de Jong, D. J., Pierik, M., van der Woude, C. J., Romberg-Camps, M. J. L., Clemens, C. H., Jansen, J. M., Mahmmod, N., van de Meeberg, P. C., van der Meulen-de Jong, A. E., Ponsioen, C. Y., Bolwerk, C. J., Vermeijden, J. R., Siersema, P. D., . . . on behalf of the COIN study group and the Dutch Initiative on Crohn and Colitis. (2014). Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study. Gut. https://doi.org/10.1136/gutjnl-2012-303376

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.